| Ruling Favors Anthrax-Vaccine Maker Biotechnology company, PharmAthene, won a ruling allowing it to keep a government contract worth about $78 million for developing a new anthrax vaccine. online.wsj.com |
Researchers Try to Create Human Skin A look at how scientists are trying to grow cells into natural skin. The result could someday replace skin grafting as a treatment for burn victims and those with chronic skin wounds. online.wsj.com |
China Nuokang Bio-Pharmaceutical Inc. Appoints Huining Cao to Board of Directors (GlobeNewswire) BEIJING -- China Nuokang Bio-Pharmaceutical Inc. , a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that Mr. us.rd.yahoo.com |
Arena Pharma’s Diet Pill and Tumors: A Big Rat? Pharmalot submits: No one at Arena Pharmaceuticals (ARNA) could accuse CEO Jack Lief of being a rat. In a conference call Thursday with analysts after an FDA panel rejected the drugmaker’s Lorqess diet pill due to safety concerns, Lief acknowledged that different forms of cancer had been seen in rats treated with high doses. But he stressed that “when we learned of the data, we promptly discussed it with the FDA.” But then Cowen analyst Phil Nadeau asked if the info was ever made available to the public or was the FDA briefing document (pdf) released this week the first time investors might have learned of this finding. Lief replied by saying “…we believe that (Lorqess) does not pose a cancer risk to humans at the recommended therapeutic dose…There is an immense amount of data generated in drug development. We did not, and still do not believe that the data’s relevant to humans and, as such, did not believe it was material to investors.”Complete Story » seekingalpha.com |
LTX-Credence CEO Discusses F1Q2011 Results - Earnings Call Transcript LTX-Credence CorporationF1Q2011 (Qtr 10/31/10) Earnings Conference CallNovember 23, 2010 10:00 AM ETComplete Story » seekingalpha.com |